GLP-1REWIN

Unknown

GLP-1 REceptor Agonists and Real World EvIdeNce

Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study

Lead sponsor

University of Padova

Assets

Dulaglutide / Exenatide / Liraglutide / Lixisenatide

Listed sites

Recruiting sites

—

Enrollment

6,000

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03959865

Org study ID4462/AO/18

Timeline

Milestones

Study start2018-12-19actual

Primary completion2019-02-11actual

Study first posted2019-05-22actual

Last update posted2019-05-22actual

Study completion2019-05-31estimated

Assets

Investigational agents

Dulaglutide Exenatide Liraglutide Lixisenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Sampling methodNon probability sample

Study population text

Type 2 diabetic patients attending diabetes specialist clinics in North East Italy.

Inclusion criteria

•Type 2 diabetes

•Diabetes duration of at least 1 year

•Initiated on a GLP-1RA during the data collection period

Exclusion criteria

•Type 1 diabetes

•Previous therapy with a GLP-1RA before the data collection period

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Cardiometabolic biomarkers

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Weight

Time frame:3-12 months

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

HbA1c

Time frame:3-12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Blood pressure

Time frame:3-12 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Persistence

Time frame:3-12 months

threshold achievement, descriptive

Publications (6)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
Diabetes, obesity & metabolism2019 Nov (month)PMID31364233doi:10.1111/dom.13840via clinicaltrials gov reference derived + pubmed nct search
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes care2018 Dec (month)PMID30291106doi:10.2337/dci18-0033via CT.gov background
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
The lancet. Diabetes & endocrinology2018 Feb (month)PMID29221659doi:10.1016/S2213-8587(17)30412-6via CT.gov background
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
Diabetes, obesity & metabolism2017 Feb (month)PMID27717195doi:10.1111/dom.12804via CT.gov background
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes, obesity & metabolism2017 Feb (month)PMID27717130doi:10.1111/dom.12805via CT.gov background
Incretin-based therapies for type 2 diabetes mellitus.
Nature reviews. Endocrinology2009 May (month)PMID19444259doi:10.1038/nrendo.2009.48via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.